|Bid||3.7600 x 900|
|Ask||4.1500 x 3000|
|Day's Range||3.7700 - 4.0800|
|52 Week Range||2.2700 - 21.6300|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.33|
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.